在单克隆抗体治疗策略方面已取得重大进展。这些进展包括修改它们的格式、生产和功能化，进一步提高了它们的功效，特别是在肿瘤学方面，帮助克服了几个限制。然而，抗体药物复合物的疗效和安全性还不够理想。本文主要总结了在肿瘤学中开发抗体药物复合物的各种策略需要解决的挑战。作者还提供了他们的专业意见和未来展望。解决本文讨论的挑战，如改进靶向癌细胞的特异性、将细胞毒性药物选择性地位点特异性地结合到抗体上，并开发不同的策略来克服药物耐受性问题，可能会产生一类新的ADC，并为ADC的概念带来更多价值，特别是在肿瘤患者的治疗方面。

There have been significant advances in the therapeutic strategies based on monoclonal antibodies. These advances, including the modification of their format, their production, and their functionalization. have further improved their efficacy and, particularly in oncology, have helped to overcome several limitations. Nevertheless, the efficacy and safety profile of antibody drug conjugates is not yet optimal.This article primarily summarizes the challenges that need to be addressed during the development of various strategies for the discovery of antibody-drug conjugates in oncology. The authors further provide their expert opinion and perspectives for the future/.Addressing the challenges discussed in this perspective, such as by improving the specificity of targeting cancer cells, the selective site-specific conjugation of cytotoxic drugs to antibodies and developing different strategies to overcome the problem of drug resistance will likely generate a new class of ADCs and bring more value to the concept of ADCs, particularly in the treatment of cancer patients.